Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Discussions at a Community Case Forum event emphasized the importance of listening to patient concerns and a multidisciplinary approach when treating advanced endometrial cancer.

Trial data support potential treatment options with durvalumab-based regimens for advanced or recurrent endometrial cancer.